Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications.
angiogenesis
angiogenic cytokines
extracellular vesicles
multiple myeloma
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
08 May 2023
08 May 2023
Historique:
received:
04
01
2023
revised:
20
04
2023
accepted:
27
04
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Extracellular vesicles (EVs) have emerged as important players in cell-to-cell communication within the bone marrow (BM) of multiple myeloma (MM) patients, where they mediate several tumor-associated processes. Here, we investigate the contribution of fibroblasts-derived EVs (FBEVs) in supporting BM angiogenesis. We demonstrate that FBEVs' cargo contains several angiogenic cytokines (i.e., VEGF, HGF, and ANG-1) that promote an early over-angiogenic effect independent from EVs uptake. Interestingly, co-culture of endothelial cells from MM patients (MMECs) with FBEVs for 1 or 6 h activates the VEGF/VEGFR2, HGF/HGFR, and ANG-1/Tie2 axis, as well as the mTORC2 and Wnt/β-catenin pathways, suggesting that the early over-angiogenic effect is a cytokine-mediated process. FBEVs internalization occurs after longer exposure of MMECs to FBEVs (24 h) and induces a late over-angiogenic effect by increasing MMECs migration, chemotaxis, metalloproteases release, and capillarogenesis. FBEVs uptake activates mTORC1, MAPK, SRC, and STAT pathways that promote the release of pro-angiogenic cytokines, further supporting the pro-angiogenic milieu. Overall, our results demonstrate that FBEVs foster MM angiogenesis through dual time-related uptake-independent and uptake-dependent mechanisms that activate different intracellular pathways and transcriptional programs, providing the rationale for designing novel anti-angiogenic strategies.
Identifiants
pubmed: 37239071
pii: biomedicines11051400
doi: 10.3390/biomedicines11051400
pmc: PMC10216205
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : 25706
Organisme : Regione Puglia
ID : INNOLABS-POR FESR-FSE 2014-2020 (Telemielolab)
Organisme : Italian Ministry for Education, University and Research
ID : 20174TB8KW002
Références
Cancers (Basel). 2023 Mar 27;15(7):
pubmed: 37046651
Cell Commun Signal. 2022 Apr 7;20(1):49
pubmed: 35392964
J Clin Med. 2020 Jun 06;9(6):
pubmed: 32517267
Front Oncol. 2021 Feb 09;10:625199
pubmed: 33634031
Am J Pathol. 2021 Apr;191(4):748-758
pubmed: 33516787
Biomedicines. 2020 Nov 06;8(11):
pubmed: 33171974
Blood. 2014 Dec 11;124(25):3748-57
pubmed: 25320245
Leukemia. 2016 Mar;30(3):640-8
pubmed: 26487273
J Pathol. 2022 Apr;256(4):402-413
pubmed: 34919276
Oncotarget. 2016 Mar 22;7(12):14510-21
pubmed: 26919105
Thromb Haemost. 2004 Dec;92(6):1438-45
pubmed: 15583754
Dev Cell. 2019 Feb 25;48(4):573-589.e4
pubmed: 30745143
Front Cell Dev Biol. 2020 Jul 07;8:584
pubmed: 32775327
Front Cell Dev Biol. 2016 Sep 21;4:99
pubmed: 27709112
Chem Immunol Allergy. 2014;99:180-96
pubmed: 24217610
Transl Oncol. 2021 Dec;14(12):101231
pubmed: 34601397
PLoS One. 2020 Apr 10;15(4):e0231430
pubmed: 32275689
Oncogene. 2019 Jun;38(26):5227-5238
pubmed: 30890754
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood. 2003 Nov 1;102(9):3340-8
pubmed: 12855563
J Hematol Oncol. 2019 Jan 9;12(1):4
pubmed: 30626425
Front Oncol. 2021 Jun 21;11:689538
pubmed: 34235082
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4852-7
pubmed: 21368175
Cell Rep. 2021 May 18;35(7):109139
pubmed: 34010648
Oncotarget. 2018 Apr 17;9(29):20563-20577
pubmed: 29755672
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Front Immunol. 2016 Sep 22;7:378
pubmed: 27713747
Clin Cancer Res. 2014 Nov 15;20(22):5796-807
pubmed: 25212607
Proteomics. 2021 Jul;21(13-14):e2000119
pubmed: 33580572
Front Cell Dev Biol. 2022 Jul 08;10:919438
pubmed: 35874817
Lancet. 2021 Jan 30;397(10272):410-427
pubmed: 33516340
Oncotarget. 2014 Jul 30;5(14):5686-99
pubmed: 25015330
Angiogenesis. 2005;8(1):43-51
pubmed: 16132617
Sci Rep. 2018 Jun 12;8(1):8973
pubmed: 29895824
Nat Rev Mol Cell Biol. 2022 May;23(5):369-382
pubmed: 35260831
J Immunol. 2006 Jun 15;176(12):7385-93
pubmed: 16751383
J Clin Med. 2022 Nov 01;11(21):
pubmed: 36362718
Curr Cancer Drug Targets. 2008 Feb;8(1):19-26
pubmed: 18288940
J Pathol. 2016 Jun;239(2):162-73
pubmed: 26956697
Front Oncol. 2021 Aug 27;11:718502
pubmed: 34513695
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
Blood Adv. 2017 May 16;1(13):812-823
pubmed: 29296725
Leukemia. 2014 Apr;28(4):904-16
pubmed: 23995611
J Exp Med. 1996 Mar 1;183(3):1161-72
pubmed: 8642258
J Extracell Vesicles. 2021 Sep;10(11):e12140
pubmed: 34520123
J Allergy Clin Immunol. 2010 Feb;125(2):477-82
pubmed: 20159258
Int J Mol Sci. 2018 Jul 12;19(7):
pubmed: 30002349